A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression

NCT00703742 | Completed DMC

• 1 other identifier: Kunming MC
• Study Type: interventional
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is:

1. 1.to find out the structural or functional effects of selective serotonin reuptake inhibitors (SSRI) in major depressive disorder (MDD);
2. 2.find special abnormalities in depression secondary to other disease, e.g., autoimmune disease like systemic lupus erythematosus (SLE).
3. 3.find the relationship between the efficacy of antidepressant and the change of neuroimaging in MDD
4. 4.to find possible predispose to MDD
5. 5.to explore the DNA methylation status in depression;

Conditions

Depression; Depression Secondary to Other Disease

Outcome Measures

Primary Outcomes (1)

• change of fMRI after medication

  baseline, 4 weeks, 8 weeks

Study Arms (1)

A,1

EXPERIMENTAL

A: Escitalopram, 20 mg/day,8weeks

Drug: Escitalopram

Interventions

Escitalopram DRUG

A,1: Escitalopram, oral, 20 mg/day, 8 weeks

A,1

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• DSM-IV Major Depression or Dysthymia
• Age 18-65
• Physically healthy
• Drug-free

You may not qualify if:

• Body metal (e.g., wire stitches, screws in bones, stainless steel hips)
• History of Psychosis or Epilepsy
• Current (past six months) Substance Use Disorder (illicit drugs and/or alcohol)
• Bipolar I
• Need for wash-out from effective treatment in order to participate
• Pregnant
• High suicide risk
• Currently taking (within 2 weeks; 4 weeks for Fluoxetine) antidepressants

Sponsors & Collaborators

• Kunming Medical University: lead
• Chinese Academy of Sciences: collaborator

Study Sites (1)

The First Affiliated Hospital of Kunming Medical College

Kunming, Yunnan, 650031, China

Location

Related Publications (3)

• Chu Z, Yuan L, He M, Cheng Y, Lu Y, Xu X, Shen Z. Atrophy of bilateral nucleus accumbens in melancholic depression. Neuroreport. 2023 Jun 7;34(10):493-500. doi: 10.1097/WNR.0000000000001915. Epub 2023 May 31.

  PMID: 37270840 DERIVED

• Cheng Y, Xu J, Yu H, Nie B, Li N, Luo C, Li H, Liu F, Bai Y, Shan B, Xu L, Xu X. Delineation of early and later adult onset depression by diffusion tensor imaging. PLoS One. 2014 Nov 13;9(11):e112307. doi: 10.1371/journal.pone.0112307. eCollection 2014.

  PMID: 25393297 DERIVED

• Xu J, Cheng Y, Chai P, Lu Z, Li H, Luo C, Li X, Li L, Zhou Q, Chen B, Cao J, Xu X, Shan B, Xu L, Wen J. White-matter volume reduction and the protective effect of immunosuppressive therapy in systemic lupus erythematosus patients with normal appearance by conventional magnetic resonance imaging. J Rheumatol. 2010 May;37(5):974-86. doi: 10.3899/jrheum.090967. Epub 2010 Mar 15.

  PMID: 20231206 DERIVED

MeSH Terms

Conditions

Depression

Interventions

Escitalopram

Condition Hierarchy (Ancestors)

Behavioral Symptoms; Behavior

Intervention Hierarchy (Ancestors)

Propylamines; Amines; Organic Chemicals; Nitriles; Benzofurans; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Officials

• Xu Xiufeng

  Kunming Medical University

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Vise director, psychiatry department, Kunming Medical University

Study Record Dates

• First Submitted: June 20, 2008
• First Posted: June 23, 2008
• Study Start: June 1, 2008
• Primary Completion: June 1, 2011
• Study Completion: June 1, 2011
• Last Updated: September 17, 2019

Record last verified: 2019-09

Locations

CN (1)